Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Genentech, Constellation Enter Largest Epigenetics Tie-Up Yet

This article was originally published in The Pink Sheet Daily

Executive Summary

For $95 million guaranteed, Genentech gains rights to broad research in the emerging field over a three-year period, as well as an option to acquire the start-up outright.


Related Content

Third Rock Ventures Rolls Its Own
Few Exits, But Lots Of Cash: Third Rock Closes $516M Third Fund
Seeking Drugs “Hidden In Microbes,” Third Rock Launches Warp Drive Bio
Cancer Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Genentech Licenses A Cancer Metabolism Program From Forma, With Option To Buy
Eisai Deal Puts Epizyme In Position To Advance Lead Program
GSK Teams Up With EpiZyme To Develop Epigenetic Drugs
Abbott Adds Epigenetics To Its Anticancer R&D Through EpiTherapeutics Deal
Constellation Brings In Series B Totaling $22 Million, Including GSK Investment
The Epigenetics (R)evolution


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts